510(k) Report

510(k) · Cleared

Cleared

Immulite 2000 Tobramycn, Models L2KTC2 (2002 Tests), L2KTC6 (600 Tests)

K012312510(k) TraditionalCleared Aug 20, 200128-day reviewClass II21 CFR 862.3900

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Diagnostic Products Corp. · KLB Radioimmunoassay, Tobramycin

Cleared on Aug 20, 2001 as substantially equivalent to K941614 (Abbott Laboratories, 1994) after a 28-day review. Its family tree reaches back 1 generation to 1994.

Decided
Aug 20, 2001
Review
28 days
Class
Class II
Product code
KLB
Recalls
None
Predicates
1

Its longest line of descent runs back 1 generation to K941614 (1994). No later device cites it as a predicate yet.

K941614 · Axsym Tobramycin · Abbott Laboratories · 19941990199219941996199820002002
K941614 · Axsym Tobramycin · Abbott Laboratories · 19940
  1. Root · 1 generation backK941614 Axsym TobramycinAbbott Laboratories · 1994
  2. This deviceK012312 Immulite 2000 Tobramycn, Models L2KTC2 (2002 Tests), L2KTC6 (600…Diagnostic Products Corp. · 2001
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−1K941614Axsym TobramycinAbbott Laboratories1994—
0 (this device)K012312Immulite 2000 Tobramycn, Models L2KTC2 (2002 Tests), L2KTC6 (600 Tests)Diagnostic Products Corp.2001—
FIG. 1 — Lineage of K012312, 1994–2001Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in KLB? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K941614Axsym Tobramycin
Summary page 2
…geles, CA 90045-5597 Establishment Registration #: DPC's establishment Registration No. is 2017183 Substantially Equivalent Predicate Device: Abbott AxSYM® Tobramycin (K941614) Description of Device: IMMULITE® 2000 Tobramycin is a solid-phase, chemiluminescent enzyme immunoassay for use with the IMMULI…
Abbott Laboratories1994—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Its one ancestor has no recall.

How does its category compare?

All KLB devices

KLB Radioimmunoassay, Tobramycin: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · KLB

FDA has decided no KLB device since 2007.

Median 510(k) review, days · KLB

Too few KLB 510(k)s in any year since 2007 to give a median.

Recalls per year · KLB

2in 2007

2007: 2
2007high 2 (2007) · low 0 (2008)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · KLB

1in 2024

2017: 12024: 1
2007high 1 (2017) · low 0 (2007)2025

MAUDE reports naming product code KLB, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—20
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—01
20180—00
20190—00
20200—00
20210—00
20220—00
20230—00
20240—01
20250—00
20260—0—

What is it indicated for?

For in vitro diagnostic use with the IMMULITE 2000 Analyzer — for the quantitative measurement of tobramycin in serum or plasma, as an aid in monitoring the therapeutic administration of this aminoglycoside.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K012312: Immulite 2000 Tobramycn, Models L2KTC2 (2002 Tests), L2KTC6 (600 Tests).” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K012312

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 30, 2026 (extraction version 2d9447fa9ea4)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026